Eterna Therapeutics, Inc. (ERNA) has announced promising findings from a preclinical study of its leading cell therapy product, ERNA-101. This therapy is crafted to activate and regulate the immune system’s ability to identify and eliminate ovarian cancer cells.
The proof-of-concept study showed significant infiltration of T cells after administering a single dose of ERNA-101, resulting in a decreased tumor burden and prolonged survival in mice with ovarian cancer.
ERNA-101 holds potential not only for enhanced therapeutic results as a standalone treatment but is also projected to boost the effectiveness of CAR-T and CAR-NK cell therapies in the future.
The therapy employs induced pluripotent stem cells (iPSCs) to develop induced allogenic mesenchymal stem cells (iMSCs), which release interleukins IL-7 and IL-15. These cytokines bolster the immune system's response against tumors by improving immune cell infiltration and activation.
